Ad
MURA Stock - Mural Oncology plc Stock Trading
About | Mural Oncology plc (NASDAQ:MURA)
Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab.
Quote | Mural Oncology plc (NASDAQ:MURA)
| Last: | $2.64 |
|---|---|
| Change Percent: | 0.36% |
| Open: | $2.76 |
| Close: | $2.64 |
| High: | $2.77 |
| Low: | $2.53 |
| Volume: | 786,425 |
| Last Trade Date Time: | 04/24/2025 03:39:48 pm |
News | Mural Oncology plc (NASDAQ:MURA)
-
2025-04-15 16:55:00 ET A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives. Traders rushed to buy up sh...
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
Message Board Posts | Mural Oncology plc (NASDAQ:MURA)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
Mural Oncology plc Company Name:
MURA Stock Symbol:
NASDAQ Market:
0.36% G/L:
$2.64 Last:
786,425 Volume:
$2.76 Open:
$2.64 Close:
Ad
-
2025-04-15 16:55:00 ET A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives. Traders rushed to buy up sh...
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
-
2025-04-15 08:47:35 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com )- Mural Oncology (NASDAQ:MURA) stated that it’s halting all clinical development of nemvaleukin alfa and launching a high-stakes hunt for strategic alternatives to maximize shareholder value, backed by a heft...